Individuals who may be at greater risk include: Those with a pre-existing diagnosis of osteoarthritis, rheumatoid arthritis, or other inflammatory joint conditions Patients with obesity-related joint loading, particularly affecting the knees, hips, and lower back Older adults, in whom musculoskeletal complaints are more prevalent at baseline Individuals experiencing rapid weight loss, which may transiently alter joint mechanics and gait, particularly in the lower limbs this is a theoretical consideration based on general musculoskeletal principles rather than retatrutide-specific evidence Significant weight reduction one of retatrutide's primary therapeutic effects is generally associated with reduced mechanical load on weight-bearing joints , which may improve joint symptoms over time in individuals with obesity-related arthropathy
This allows the study to observe the effects of the primary agent in isolation
[3] Long-distance runners supplementing with 2g of l-carnitine twice a day showed marked increases in the presence of many of these enzymes, suggesting that l-carnitine actually helps the body work more efficiently down at the cellular level
By aligning patient biology with drug discovery, Phenomix is shaping a more personalized and impactful future for obesity treatment
About 11% quit the trial because of side effects
.png.jpg)
